Leap Therapeutics Inc LPTX:NASDAQ

Last Price$1.17NASDAQ Previous Close - Last Trade as of 4:00PM ET 7/01/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$1.17 (1)
Ask (Size)$1.26 (21)
Day Low / HighN/A - N/A
Volume263.4 K

View Biotechnology IndustryPeer Comparison as of 07/01/2022


Leap Therapeutics Inc ( NASDAQ )

Price: $1.17
Change: +0.02 (1.74%)
Volume: 263.4 K
4:00PM ET 7/01/2022

Enzo Biochem Inc ( NYSE )

Price: $2.14
Change: +0.07 (3.38%)
Volume: 35.0 K
7:00PM ET 7/01/2022

Enochian Biosciences Inc ( NASDAQ )

Price: $1.93
Change: 0.00 (0.00%)
Volume: 1.0 M
4:00PM ET 7/01/2022

Entasis Therapeutics Holdings Inc ( NASDAQ )

Price: $2.19
Change: -0.01 (0.45%)
Volume: 49.3 K
4:00PM ET 7/01/2022

Homology Medicines Inc ( NASDAQ )

Price: $1.83
Change: -0.14 (7.11%)
Volume: 187.0 K
4:00PM ET 7/01/2022

Read more news Recent News

Piper Sandler Adjusts Leap Therapeutics' Price Target to $4 From $6, Reiterates Overweight Rating
5:14AM ET 5/31/2022 MT Newswires

Leap Therapeutics (LPTX) has an average rating of outperform and price targets ranging from $4 to $6, according to analysts polled by Capital IQ. (MT...

Leap Therapeutics, Leica Team Up to Develop Companion Diagnostic for Cancer Patients
7:51AM ET 1/31/2022 MT Newswires

Leap Therapeutics (LPTX) said Monday that it has teamed up with Leica Biosystems to develop a companion diagnostic to detect Dickkopf-related protein 1....

--Piper Sandler Adjusts Leap Therapeutics' Price Target to $6 From $5, Reiterates Overweight Rating
5:05AM ET 1/24/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Sector Update: Health Care Stocks Edge Higher Premarket Wednesday
9:12AM ET 1/19/2022 MT Newswires

Health care stocks were edging higher premarket Wednesday. The iShares Biotechnology ETF (IBB) was up by 0.64% while the Health Care SPDR (XLV) was 0.02%...

Company Profile

Business DescriptionLeap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA. View company web site for more details
Address47 Thorndike Street
Cambridge, Massachusetts 02141
Number of Employees25
Recent SEC Filing06/16/20228-K
President, CEO, CFO, Secretary & TreasurerDoug E. Onsi
Chief Operating OfficerAugustine J. Lawlor
Chief Medical OfficerCynthia Sirard
Head-ResearchMichael Haas

Company Highlights

Price Open$1.14
Previous Close$1.15
52 Week Range$0.92 - 4.17
Market Capitalization$103.3 M
Shares Outstanding88.3 M
SectorHealth Technology
Next Earnings Announcement08/12/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.48
Beta vs. S&P 500N/A
Net Profit Margin-3,718.13%
Return on Equity-47.38%

Analyst Ratings as of 05/13/2022

Consensus RecommendationConsensus Icon
Powered by Factset